AstraZeneca's Acquisition of SixPeaks Signals Pharma's Urgent Push into Muscle Preservation
Melbourne, Australia — 23 October 2025
AstraZeneca today completed its acquisition of SixPeaks Bio for up to US$300 million, adding a preclinical muscle-preservation biologic to its obesity franchise. The deal — struck at preclinical stage — underscores just how aggressively major pharmaceutical companies are moving to address muscle loss in weight management patients.
SixPeaks was developing a bispecific antibody targeting activin receptors. That it commanded a US$300 million price tag while still preclinical reflects the scarcity of credible assets in the muscle preservation space and the strategic importance pharma is placing on solving this problem.
"AstraZeneca paying US$300 million for a preclinical biologic confirms the commercial urgency here," said Executive Chair Dr. Greg Collier. "Imitex is developing a first-in-class oral small molecule with a validated mechanism and demonstrated proof-of-concept data — and no direct competition. The strategic logic for a pharma partnership or acquisition is compelling."